Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons

Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and / or the absence of said biopolymer.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] This application is a continuation of application Ser. No. 09 / 846,328, filed on Apr. 30, 2001, the contents of which is herein incorporated by reference.FIELD OF THE INVENTION [0002] This invention relates to the field of characterizing the existence of a disease state; particularly to the utilization of mass spectroscopy to elucidate particular biopolymer markers indicative of disease state, and most particularly to specific biopolymer sequences having a unique relationship to at least one particular disease state. BACKGROUND OF THE INVENTION [0003] Methods utilizing mass spectrometry for the analysis of a target polypeptide have been taught wherein the polypeptide is first solubilized in an appropriate solution or reagent system. The type of solution or reagent system, e.g., comprising an organic or inorganic solvent, will depend on the properties of the polypeptide and the type of mass spectrometry performed and are well known in the ...

AI Technical Summary

Benefits of technology

This approach enables the characterization of disease states by identifying specific biopolymer markers, facilitating early diagnosis and prevention of conditions like diabetes, heart failure, and cardiovascular events, and providing tools for rapid diagnosis of acute events like heart attacks and strokes.

Problems solved by technology

On the contrary, the '396 patent requires a complicated analysis by a highly trained individual to determine disease state versus the perception of non-disease or normal physiology.

Furthermore, note that some EAM when used as free chemicals to embed analyte molecules as described for the MALDI process will not work (i.e., they do not promote molecular desorption, thus they are not suitable matrix molecules).

Retentate chromatography is limited, however, by the fact that if unfractionated body fluids, e.g. blood, blood products, urine, saliva, and the like, along with tissue samples, are applied to the adsorbent surfaces, the biopolymers present in the greatest abundance will compete for all the available binding sites and thereby prevent or preclude less abundant biopolymers from interacting with them, thereby reducing or eliminating the diversity of biopolymers which are readily ascertainable.

Images